Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

Autor:	Sweeney, Christopher1 (AUTHOR), Bracarda, Sergio2 (AUTHOR), Sternberg, Cora N3 (AUTHOR), Chi, Kim N4 (AUTHOR), Olmos, David5,6 (AUTHOR), Sandhu, Shahneen7 (AUTHOR), Massard, Christophe8 (AUTHOR), Matsubara, Nobuaki9 (AUTHOR), Alekseev, Boris10 (AUTHOR), Parnis, Francis11 (AUTHOR), Atduev, Vagif12 (AUTHOR), Buchschacher, Gary L13 (AUTHOR), Gafanov, Rustem14 (AUTHOR), Corrales, Luis15 (AUTHOR), Borre, Michael16 (AUTHOR), Stroyakovskiy, Daniil17 (AUTHOR), Alves, Gustavo Vasconcelos18 (AUTHOR), Bournakis, Evangelos19 (AUTHOR), Puente, Javier20 (AUTHOR), Harle-Yge, Marie-Laurence21 (AUTHOR)
Zdroj:	Lancet. Jul2021, Vol. 398 Issue 10295, p131-142. 12p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu